Author of

• 11946

  +

  P2.24 - Poster Session 2 - Supportive Care (ID 157)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Supportive Care
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11990

    +

    P2.24-044 - Use and comparison of erythropoiesis-stimulating agents (ESAs) for the treatment of chemotherapy-induced anaemia (CIA) in patients with non-small cell lung cancer (NSCLC) (ID 2617)

    09:30 - 09:30  |  Author(s): F. Rebollo
    • Abstract

    Background
    There are limited data on the relative effectiveness of biosimilar ESAs and other available ESAs for the treatment of CIA. In addition, it is unclear whether the most recent recommendations for more conservative use of ESAs to treat CIA are reflected in real-world clinical practice

    Methods
    We analysed 73 patients with NSCLC who were included in a retrospective audit of CIA treatment with ESAs in a large oncology centre in Spain, with patients treated by multiple physicians. The patients were treated for CIA with Binocrit[®] 40,000 IU QW (n=12), Binocrit[®] 30,000 IU QW (n=6), darbepoetin alfa 500 μg Q3W (n=36) or darbepoetin alfa 150 μg QW (n=19). In addition to overall haemoglobin (Hb) outcomes, comparisons were performed according to the different ESA treatments given

    Results
    The mean overall haemoglobin (Hb) at start of ESA treatment was 9.4 g/dL; the mean overall Hb level at the end of treatment was 10.6 g/dL. 36/73 patients (49%) achieved a Hb increase of at least 1 g/dL. There were no significant differences (p>0.05) between the groups in terms of Hb levels at the start of ESA treatment. At the end of treatment, however, the mean Hb level in the group treated with darbepoetin alfa 500 μg Q3W was significantly lower than that in the other three groups (Table). No drug-related adverse events were recorded

    ESA	Mean treatment duration (weeks)	Mean Hb at start of treatment (g/dL)	Mean Hb at end of treatment (g/dL)
    Darbepoetin 150 μg QW	4.16	9.2	11.3
    Darbepoetin 500 μg Q3W	4.59	9.4	10.1
    Binocrit 30,000 IU	3.50	9.4	11.1
    Binocrit 40,000 IU	3.67	9.5	10.7

    Conclusion
    Our data indicate that Hb outcomes in a real-world clinical practice setting are similar for the ESA treatments used with the exception of Darbepoetin 500 μg Q3W, which achieved a significantly lower Hb at the end of treatment. We consider the use of ESAs in our centre to be conservative and safe, and to reflect the most recent change in ESA prescribing information and recommendations for more moderated use in patients with CIA (that is, use the lowest possible dose and duration of treatment necessary to avoid transfusions)